Kilitch Drugs (India) Limited (KILITCH) Share Price
NSE · Healthcare · Drug Manufacturers - Specialty & Generic · ISIN INE729D01010
Key metrics
- Market Cap
- ₹603 Cr
- P/E Ratio
- 19.66
- EPS
- 8.81
- Book Value
- 79.19
- P/B Ratio
- 2.17
- ROE
- 10.9%
- ROCE
- 9.02%
- Debt / Equity
- 0.32
- Net Margin
- 12.81%
- Revenue Growth
- 18.74%
- Profit Growth
- 12.98%
- Dividend Yield
- —
- 52W High
- ₹219.50
- 52W Low
- ₹117.25
- Market Cap Band
- small cap
- Face Value
- 10
Ratios computed from the annual results period ending 2026-03-31.
About Kilitch Drugs (India) Limited
Kilitch Drugs (India) Limited engages in the development and operation of the pharmaceutical business in India and internationally. The company offers various parenteral, nasal, and topical products, such as liquid ampoules, vials, dry powder injectables, and metered nasal drops for gastroenterology, non-steroidal anti-inflammatory, anticonvulsant/antiepileptic, anti-malarial, aminoglycoside, antibacterial, anti-hypertensive, anti-infective, diagnostic, sympathomimetic, local anesthetic, neurotonic, uterine stimulant, external preparation, anticoagulant, narcotic, oncology, ophthalmic, antifungal, corticosteroid, anticoagulant, and other applications, as well as vaccines, veterinary products, iron supplements for anemia, Klavmox, and Onecef. It also provides oral formulations, including tablets, capsules, dry syrup, and oral powder for antibiotic, anti-diabetic, cardiovascular, and other areas; effervescent tablets and powders, such as Roipar, Duregra, and Roivit; and nutritional products, including Celtine. In addition, the company offers cosmetics, which include oil, lotion, liquid to cream, paste in skin, and personal and hair care products; herbal products for use in sore throat and prostate problems, as well as a supplement for diabetes, obesity, libido, and other conditions; ortho rehabilitation and implants; and medical devices comprising C-Seal, a skin adhesive to hold closely approximated skin edges without marks of sutures and incisions. Further, it provides PH-7, which reduces acid content of the stomach; SRO kit for treating childhood diarrhea; 9-VIT for use in surgery, extensive burns, fractures, and other trauma; and HPURE for sore throat and cough. The company exports its products. Kilitch Drugs (India) Limited was founded in 1978 and is headquartered in Mumbai, India.
- Headquarters
- Mumbai, India
- Employees
- 236
- Promoter Holding
- 71.76%
The full Kilitch Drugs (India) Limited analysis
Create a free account to open the complete KILITCH deep-dive — fourteen tabs of fundamental, technical, institutional and ownership data.
- 10-year financialsIncome statement, balance sheet and cash flow, year by year.
- Valuation & fair valueFair-value estimates, quality scores and a value grade.
- Charts & technicalsCandlestick charts, RSI, MACD, Supertrend and detected patterns.
- Shareholding historyPromoter, FII, DII and public holdings across every quarter.
- Ace investor holdingsWhich well-known investors hold it, and how their stake changed.
- Deals & insider tradesBulk and block deals, insider transactions and mutual-fund holdings.